Navigation Links
Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483
Date:11/25/2008

SUNNYVALE, Calif., Nov. 25 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced that the company has completed a Phase 1 clinical trial with PCI-27483, the company's novel, first-in-class small-molecule Factor VIIa inhibitor. The trial was conducted in sixteen (16) healthy volunteers to evaluate the safety and pharmacologic effect of PCI-27483. A single administration of PCI-27483 resulted in a linear dose response in the International Normalized Ratio (INR), a routine laboratory test used to assess the level of anticoagulation (blood-thinning).

"Single doses of PCI-27483 reliably and quickly achieved therapeutic levels of anticoagulation without adverse effects in this initial trial," said James Lowder, M.D., Vice President, Clinical Development for Pharmacyclics. "The ability to achieve precise levels of anticoagulation that can be readily measured differentiates PCI-27483 from other available anticoagulants. The Factor VIIa: tissue factor complex, the pharmacologic target of PCI-27483, has been implicated both in the progression of solid tumors and the increased incidence of venous thromboembolic events observed in many malignancies. Up-regulation of tissue factor expression is observed in pancreatic, lung, and breast cancer, and is associated with a worsened prognosis."

In the recently completed study, PCI-27483 increased the INR with minimal intra-subject variation and a half-life of ten hours. At the highest subcutaneous dose of PCI-27483 evaluated, a mean (+/-standard error) peak INR of 2.72 (+/- 0.24) was achieved one to two hours post-dosing. The trial further established doses of PCI-27483, which upon repeated dosing are expected to maintain the INR in the range of 2.0 to 3.0, the target window for treatment and prevention of thromboembolic events (i.e., formation of blood clots).


'/>"/>
SOURCE Pharmacyclics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmacyclics Announces Data and Publication Characterizing Highly-Selective HDAC Inhibitor
2. Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases
3. Pharmacyclics Reports Multiple Presentations at AACR on Its HDAC and Selective HDAC Inhibitors
4. Pharmacyclics Novel Factor VIIa Inhibitor Demonstrates Potential Inhibition of Tumor Growth in Multiple Types of Cancer
5. Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2014)... -- UBM Medica US announces that ConsultantLive ... primary care clinicians offers a photo collection with authoritative ... a variety of summer scourges.  The ... of medical menaces: poison ivy, tick-borne infections, insect bites, ... covered on Consultantlive,s topic center that includes sun and ...
(Date:7/21/2014)... CORONA, Calif. , July 21, 2014 /PRNewswire/ ... a leader in automated retailing, micro-stores, custom vending ... interest in their automated medicine dispensing systems, which ... alternative heath clinics and marijuana dispensaries. AVT,s newly ... secure storage of medicines and regulated products. ...
(Date:7/21/2014)... 2014  Zacks.com announces the list of stocks featured in ... discuss the latest news and events impacting stocks and the ... Pharmaceuticals, Inc. (Nasdaq: ANTH - Free Report ), Amgen, ... and Company (NYSE: LLY - Free Report ), Actelion ... (Nasdaq: ITMN - Free Report ). Today, ...
Breaking Medicine Technology:ConsultantLive Presents Special Coverage of Summer Scourges 2ConsultantLive Presents Special Coverage of Summer Scourges 3Technology Driving Cannabis Industry 2The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Amgen, Eli Lilly, Actelion and InterMune 2The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Amgen, Eli Lilly, Actelion and InterMune 3The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Amgen, Eli Lilly, Actelion and InterMune 4The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Amgen, Eli Lilly, Actelion and InterMune 5The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Amgen, Eli Lilly, Actelion and InterMune 6The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Amgen, Eli Lilly, Actelion and InterMune 7
... The TandemHeart circulatory support system has been granted ... Contractor (MAC) serving over 1.3 million beneficiaries and over ... United States. "We are extremely pleased with ... TandemHeart system," said  Kraig McEwen, President and CEO of ...
... July 12, 2011 Projects In Knowledge ( www.projectsinknowledge.com ... information tools for busy clinicians, has just launched its ... offered online and soon as a free iPhone/iPad ... complexities of magnetic resonance imaging (MRI) and other imaging ...
Cached Medicine Technology:TandemHeart Approved for Expanded Reimbursement 2MedImage Cases™: A New Medical e-Textbook from Projects In Knowledge® 2MedImage Cases™: A New Medical e-Textbook from Projects In Knowledge® 3
(Date:7/22/2014)... 22, 2014) With over 170,000 students now ... exposed to injuries during practice and competition, according to ... Health and the Center for Injury Research and Policy ... study, published online today by The American Journal ... players experienced 1,406 injuries over the four academic years ...
(Date:7/22/2014)... Neck, N.Y. (PRWEB) July 22, 2014 Two ... and ADHD were significantly more abused as ... study noted that stimulant treatment for ADHD children ... dependence. However, the data did not reveal causation. , Since ... it is imperative to clarify the origins and best treatment ...
(Date:7/22/2014)... The physical demands of Crossfit are ... gymnastics, kettleball lifting, calisthenics, and strongman exercises are all ... co-owner of CrossFit East Cobb, Crossfit studio ... workouts like these require high quality supplementation. ... to take in about 160 grams of protein a ...
(Date:7/21/2014)... 22, 2014 MillionaireCasket.com, a well-known casket manufacturer ... maple caskets to its website. In addition to this, ... percent off) for all these brand new items. , ... provides great caskets for its current and prospective ... caskets, and oak caskets and more. According to the company’s ...
(Date:7/21/2014)... What do romance, sex, motherhood, literature, Martha’s ... can find them all in Thea Marsh's new book, ... lives on Martha’s Vineyard with her husband and three ... and becomes entangled in a steamy affair that threatens ... think about what choices they would make. Should Miranda ...
Breaking Medicine News(10 mins):Health News:High school lacrosse players at risk of concussions other injuries 2Health News:High school lacrosse players at risk of concussions other injuries 3Health News:New Studies Reporting a Higher Incidence of Child Abuse in ADHD and Dyslexia Suggest a Need for Early Medical Treatment, Notes Dr. Harold Levinson 2Health News:New Studies Reporting a Higher Incidence of Child Abuse in ADHD and Dyslexia Suggest a Need for Early Medical Treatment, Notes Dr. Harold Levinson 3Health News:New Studies Reporting a Higher Incidence of Child Abuse in ADHD and Dyslexia Suggest a Need for Early Medical Treatment, Notes Dr. Harold Levinson 4Health News:CrossFit East Cobb Fuels Their Intense Workouts with All-Natural EnergyFirst Supplements 2Health News:CrossFit East Cobb Fuels Their Intense Workouts with All-Natural EnergyFirst Supplements 3Health News:Cheap Maple Caskets Recently Added To China Casket Manufacturer MillionaireCasket.com’s Product Line 2Health News:Thea Marsh Releases Debut Novel that Celebrates and Reaches out to Women Everywhere 2
... allergic to animals like cats often do have a reaction ... it is possible to generate a new therapy based on ... ,A protein found in cat saliva and dander, called gamma ... to cats. The latest innovation aims to activate the antibody ...
... acupuncture and strengthening exercises may help relieve pelvic girdle ... study researchers divided 386 women into three groups. One ... and the third underwent standard treatment plus stabilizing exercise ... to record their pain levels every morning and evening ...
... have a greater risk of developing blood clots say researchers, ... taking the necessary steps to prevent the clots from forming. ... the doctors were aware of the risk of blood clots ... 40 percent of the doctors who were surveyed treated their ...
... of death and heart attack can be reduced for heart ... usual dose of an anti-clotting drug before the procedure is ... balloon-tipped catheter is threaded into an artery. The balloon is ... vessel. A small synthetic tube - stent is used to ...
... it is commonly known may be a treatment for life-threatening ... in 17 children. These children were treated with intravenous administration ... which is a common problem in LTA. , It ... treated with sodium bicarbonate there was a decrease in blood ...
... antioxidants present in the juice of pomegranate may help ... is the process of plaques etc forming in the ... causing a state of atherosclerosis. This causes disturbed blood ... stress increases the risk of atherogenesis. ,The ...
Cached Medicine News:
... base with vacuum stage, porous vacuum plate, reservoir ... instructions. The Model 785 vacuum blotter quickly ... agarose gel onto a nylon membrane. Because it ... nucleic acid samples can be separated on a ...
... regulator. The Model 785 vacuum blotter ... from an agarose gel onto a nylon ... min for transfer, the nucleic acid samples ... to a membrane, and the hybridization reaction ...
Inquire...
... proven electrophoretic transfer apparatus incorporating state-of-the-art plate electrodes ... allows for a very close positioning of the ... power source such as a battery charger, creates ... exceptionally rapid and exact electrophoretic transfer. ...
Medicine Products: